scholarly journals Green-Light Autofluorescence Versus Combined Blue-Light Autofluorescence and Near-Infrared Reflectance Imaging in Geographic Atrophy Secondary to Age-Related Macular Degeneration

2017 ◽  
Vol 58 (6) ◽  
pp. BIO121 ◽  
Author(s):  
Maximilian Pfau ◽  
Lukas Goerdt ◽  
Steffen Schmitz-Valckenberg ◽  
Matthias M. Mauschitz ◽  
Divyansh K. Mishra ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Blue Light ◽  
Near Infrared ◽  
Green Light ◽  
Geographic Atrophy ◽  
Age Related Macular Degeneration ◽  
Infrared Reflectance ◽  
Near Infrared Reflectance ◽  
Age Related

scholarly journals Near-infrared reflectance imaging of neovascular age-related macular degeneration

2009 ◽  
Vol 247 (12) ◽  
pp. 1625-1633 ◽  
Author(s):  
Thomas Theelen ◽  
Tos T. J. M. Berendschot ◽  
Carel B. Hoyng ◽  
Camiel J. F. Boon ◽  
B. Jeroen Klevering
Keyword(s):  
Macular Degeneration ◽  
Near Infrared ◽  
Age Related Macular Degeneration ◽  
Infrared Reflectance ◽  
Near Infrared Reflectance ◽  
Age Related

scholarly journals A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration

2021 ◽  
Vol 10 (12) ◽  
pp. 2580
Author(s):  
Omar A. Halawa ◽  
Jonathan B. Lin ◽  
Joan W. Miller ◽  
Demetrios G. Vavvas
Keyword(s):  
Macular Degeneration ◽  
Geographic Atrophy ◽  
Age Related Macular Degeneration ◽  
Western World ◽  
Complement Factor ◽  
Complement Protein ◽  
Pivotal Phase ◽  
Complement Inhibition ◽  
Exudative Amd ◽  
Age Related

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among older adults in the Western world. While therapies exist for patients with exudative AMD, there are currently no approved therapies for non-exudative AMD and its advanced form of geographic atrophy (GA). The discovery of genetic variants in complement protein loci with increased susceptibility to AMD has led to the investigation of the role of complement inhibition in AMD with a focus on GA. Here, we review completed and ongoing clinical trials evaluating the safety and efficacy of these studies. Overall, complement inhibition in GA has yielded mixed results. The inhibition of complement factor D has failed pivotal phase 3 trials. Studies of C3 and C5 inhibition meeting their primary endpoint are limited by high rates of discontinuation and withdrawal in the treatment arm and higher risks of conversion to exudative AMD. Studies evaluating other complement members (CFB, CFH, CFI and inhibitors of membrane attack complex—CD59) are ongoing and could offer other viable strategies.

Sign in / Sign up

Export Citation Format

Share Document